FR2961400A1 - Composition, useful as antidiabetic drug, comprises mixture of aqueous extracts comprising Harungana madagascriensis, Gnetum species, Dioscorea species and Vernonia amygdalina - Google Patents
Composition, useful as antidiabetic drug, comprises mixture of aqueous extracts comprising Harungana madagascriensis, Gnetum species, Dioscorea species and Vernonia amygdalina Download PDFInfo
- Publication number
- FR2961400A1 FR2961400A1 FR1002574A FR1002574A FR2961400A1 FR 2961400 A1 FR2961400 A1 FR 2961400A1 FR 1002574 A FR1002574 A FR 1002574A FR 1002574 A FR1002574 A FR 1002574A FR 2961400 A1 FR2961400 A1 FR 2961400A1
- Authority
- FR
- France
- Prior art keywords
- species
- composition
- madagascriensis
- harungana
- gnetum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 239000006286 aqueous extract Substances 0.000 title claims abstract description 11
- 239000003472 antidiabetic agent Substances 0.000 title claims abstract description 9
- 241000218674 Gnetum Species 0.000 title claims abstract description 6
- 241001516685 Harungana Species 0.000 title claims abstract description 6
- 244000281702 Dioscorea villosa Species 0.000 title claims abstract 3
- 241001635503 Gymnanthemum amygdalinum Species 0.000 title abstract description 6
- 235000004109 Gymnanthemum amygdalinum Nutrition 0.000 title abstract description 6
- 229940127003 anti-diabetic drug Drugs 0.000 title description 3
- 235000005903 Dioscorea Nutrition 0.000 claims abstract description 5
- 235000000504 Dioscorea villosa Nutrition 0.000 claims abstract description 5
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 5
- 230000003178 anti-diabetic effect Effects 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 229940125708 antidiabetic agent Drugs 0.000 claims description 2
- 238000000889 atomisation Methods 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000015092 herbal tea Nutrition 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- 240000001689 Cyanthillium cinereum Species 0.000 claims 1
- 206010044008 tonsillitis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 3
- 230000010534 mechanism of action Effects 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- 206010012601 diabetes mellitus Diseases 0.000 description 19
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 241000234273 Dioscorea Species 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000007882 dietary composition Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 241000832224 Hypericaceae Species 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000011457 non-pharmacological treatment Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Composition pharmaceutique ou diététique utilisée comme antidiabétique La présente invention concerne une nouvelle application thérapeutique ou diététique du mélange de plusieurs plantes pour soigner le diabète du type 2 et pour réduire la glycémie. The present invention relates to a new therapeutic or dietary application of the mixture of several plants to treat type 2 diabetes and to reduce blood sugar.
Le déposant a constaté, de façon surprenante, que le mélange des extraits aqueux des plantes suivantes: harungana madagascriensis de la famille des hypericacées, gnetum spp de la famille des gnétacées, dioscorea spp de la famille des dioscoréacées, vernonia amygdalina de la famille des astéracées était utilisable, en tant que composition pharmaceutique ou diététique pour lutter contre le diabète du type 2. The applicant has found, surprisingly, that the mixture of the aqueous extracts of the following plants: harungana madagascriensis of the family Hypericaceae, gnetum spp of the family Gnétacées, dioscorea spp of the family dioscoraceae, vernonia amygdalina family of asteraceae was useful as a pharmaceutical or dietary composition for the control of type 2 diabetes.
Le diabète est une maladie chronique qui apparaît quand le pancréas ne sécrète pas assez d'insuline ou quand l'organisme utilise mal l'insuline qu'il produit. L'insuline est une hormone qui régule la concentration de sucre dans le sang. L'hyperglycémie, soit une trop grande concentration de sucre dans le sang, est un effet courant du diabète qui, avec le temps, provoque de graves lésions affectant de nombreuses parties du corps, en particulier les nerfs et les vaisseaux sanguins. Diabetes is a chronic disease that occurs when the pancreas does not secrete enough insulin or when the body misuses the insulin it produces. Insulin is a hormone that regulates the concentration of sugar in the blood. Hyperglycemia, which is a high concentration of sugar in the blood, is a common effect of diabetes, which over time causes serious damage to many parts of the body, especially nerves and blood vessels.
Le diabète de type 2 (nommé autrefois non insulinodépendant ou diabète de l'adulte) est dû à une mauvaise utilisation de l'insuline par l'organisme. Il représente 90 % des cas de diabète dans le monde et résulte principalement d'un surpoids et du manque d'exercice physique. Les symptômes peuvent être les mêmes que ceux du diabète de type 1, mais ils sont souvent moins prononcés. De ce fait, il arrive que la maladie ne soit diagnostiquée que plusieurs années après son apparition, alors qu'il y a déjà des complications. Récemment encore, ce type de diabète ne s'observait que chez les adultes mais il touche aussi maintenant les enfants obèses. L'Organisation mondiale de la Santé (OMS) estime qu'il y a plus de 180 millions de diabétiques dans le monde et qu'il y en aura plus du double en 2030. D'après les estimations, 1,1 million de personnes sont mortes du diabète en 2005. Près de 80 % des décès dus au diabète se produisent dans les pays à revenu faible ou moyen. Près de la moitié des décès imputables au diabète surviennent chez des personnes de moins de 70 ans; 55 % des personnes qui meurent de la maladie sont des femmes. L'OMS prévoit que les décès dus au diabète vont augmenter de plus de 50 % au cours des dix prochaines années si l'on ne prend pas des mesures urgentes. Surtout, ils risquent d'augmenter de plus de 80 % dans les pays à revenu moyen de la tranche supérieure entre 2006 et 2015. A la longue, le diabète peut entraîner des lésions du coeur, des vaisseaux sanguins, des yeux, des reins et des nerfs. Type 2 diabetes (formerly known as non-insulin-dependent diabetes or adult diabetes) is due to the body's misuse of insulin. It accounts for 90% of the world's diabetes cases and results mainly from overweight and lack of physical activity. The symptoms may be the same as those of type 1 diabetes, but they are often less pronounced. As a result, the disease can only be diagnosed several years after its onset, when there are already complications. Until recently, this type of diabetes was only seen in adults, but it is now also affecting obese children. The World Health Organization (WHO) estimates that there are more than 180 million diabetics worldwide and that there will be more than double that number in 2030. An estimated 1.1 million people died of diabetes in 2005. Nearly 80% of diabetes deaths occur in low- and middle-income countries. Nearly half of diabetes deaths occur in people under 70 years of age; 55% of people who die of the disease are women. WHO predicts that deaths from diabetes will increase by more than 50% over the next 10 years if urgent action is not taken. Above all, they are likely to increase by more than 80% in upper-middle income countries between 2006 and 2015. In the long run, diabetes can cause heart, blood vessel, eye, kidney and nerves.
La rétinopathie diabétique est une cause importante de cécité et résulte de l'accumulation de lésions des petits vaisseaux de la rétine. Au bout de 15 ans, environ 2 % des diabétiques perdent la vue et environ 10 % ont un grave handicap visuel. Les neuropathies diabétiques sont des lésions nerveuses causées par le diabète ; jusqu'à 50 % des diabétiques en souffrent. Les neuropathies diabétiques peuvent engendrer toutes sortes de problèmes, so mais les symptômes courants sont des fourmillements, des douleurs, un engourdissement ou une faiblesse dans les pieds et les mains. Associée à une mauvaise circulation sanguine, la neuropathie augmente le risque d'ulcère du pied pouvant nécessiter l'amputation. Le diabète figure parmi les principales causes d'insuffisance rénale. Entre 10 et 20 % des diabétiques 15 meurent d'une insuffisance rénale. Le diabète augmente le risque de cardiopathie et d'accident vasculaire cérébral. Cinquante pour cent des diabétiques meurent d'une maladie cardiovasculaire (principalement cardiopathie et accident vasculaire cérébral). Le risque global de décès est au moins deux fois plus important chez les diabétiques que chez les non 20 diabétiques. L'Afrique n'est pas épargnée par ce fléau. « Près de 14 millions de personnes ont le diabète sur l'ensemble du continent, et ce chiffre devrait presque doubler et atteindre 27 millions d'ici 2025 selon la Fédération Internationale du Diabète. La stratégie de prise en charge des patients est la suivante : 25 Quand par exemple un diabète de type Il est diagnostiqué, on a recours tout d'abord à un traitement non pharmacologique. Pendant 4 à 6 mois, le patient diabétique doit respecter les règles hygiénodiététiques citées ci-dessus : régime réduisant les aliments gras, les boissons sucrées et alcoolisées, la reprise d'une activité physique régulière pendant 30 à 45 minutes, 3 à 4 jours par semaine. Ceci 2961400 -3- permettra une perte de poids et une significative réduction des valeurs glycémiques, tensionnelles et lipidiques. En cas d'échec après 4 à 6 mois, il faut alors opter pour un traitement médicamenteux. La deuxième étape consiste à la monothérapie orale. On dispose actuellement de médicaments antidiabétiques actifs par voie orale à action hypoglycémiante. Les hypoglycémiantes per os les plus 5 connus sont: - Biguanides : ils améliorent la sensibilité à l'insuline. - Sulfamides hypoglycémiants : ils stimulent la sécrétion d'insuline et ont une activité hypoglycémiante plus marquée. - Inhibiteurs des a-glucosidases: ils ont une activité hypoglycémiante plus faible. - Insulino-secrétagogues (glinidines): ils sont surtout actifs sur l'hyperglycémie post prandiale. Ces médicaments utilisés en monothérapie permettent d'obtenir un contrôle glycémique correct qui est évalué tous les 4 mois par un dosage de l'hémoglobine glyquée (HbAlc). - l'objectif optimal à atteindre est une valeur d'HbAlc inférieure ou égale à 6,5%. - lorsque l'HbA1c se situe entre 6,6 et 8% sur deux contrôles successifs, une modification du traitement peut-être envisagée en fonction de l'appréciation par le clinicien du rapport avantages/inconvénients du changement de traitement envisagé - lorsque l'HbAlc est supérieure à 8% sur deux contrôles successifs, une modification du traitement est recommandée (accord professionnel). La troisième étape est la bithérapie orale. En cas d'échec primaire ou secondaire de la monothérapie orale initiale, il est recommandé de prescrire une bithérapie orale c'est à dire d'associer entre elles deux classes d'hypoglycémiants. La quatrième étape est l'insulinothérapie. Si un diabétique de type II demeure mal équilibré, il faut passer à un traitement par l'insuline. L'insulinothérapie permet d'obtenir une amélioration nette du contrôle glycémique. Si ce n'est pas le cas, on peut associer à l'insulinothérapie la prescription de biguanides qui en potentialisent l'action. Le but de l'invention est donc de proposer une nouvelle composition pharmaceutique et/ou diététique qui agit comme un antidiabétique, sans effets secondaires notables. Diabetic retinopathy is an important cause of blindness and results from the accumulation of lesions of the small vessels of the retina. After 15 years, about 2% of people with diabetes lose their sight and about 10% have severe visual impairment. Diabetic neuropathies are nerve damage caused by diabetes; up to 50% of diabetics suffer from it. Diabetic neuropathies can cause all kinds of problems, but common symptoms include tingling, pain, numbness, or weakness in the feet and hands. Associated with poor blood circulation, neuropathy increases the risk of foot ulcers that may require amputation. Diabetes is one of the leading causes of kidney failure. Between 10 and 20% of diabetics die of renal failure. Diabetes increases the risk of heart disease and stroke. Fifty percent of people with diabetes die of cardiovascular disease (mainly heart disease and stroke). The overall risk of death is at least twice as high in diabetics than in non-diabetics. Africa is not spared by this scourge. "Nearly 14 million people have diabetes across the continent, and this number is expected to nearly double to 27 million by 2025, according to the International Diabetes Federation. The patient management strategy is as follows: When for example type II diabetes is diagnosed, non-pharmacological treatment is first used. For 4 to 6 months, the diabetic patient must abide by the rules of diet and diet mentioned above: diet that reduces fatty foods, sugary and alcoholic beverages, regular physical activity for 30 to 45 minutes, 3 to 4 days week. This will allow for weight loss and a significant reduction in glycemic, blood pressure and lipid values. In case of failure after 4 to 6 months, it is then necessary to opt for a drug treatment. The second step is oral monotherapy. At present, active antidiabetic drugs are available which have a hypoglycemic action. The most known oral hypoglycemic agents are: Biguanides: they improve the sensitivity to insulin. - Hypoglycemic sulphonamides: they stimulate the secretion of insulin and have a more marked hypoglycemic activity. - Inhibitors of α-glucosidases: they have a lower hypoglycemic activity. - Insulin secretagogues (glinidins): they are mainly active on postprandial hyperglycaemia. These drugs used in monotherapy allow to obtain a correct glycemic control which is evaluated every 4 months by an assay of the glycated hemoglobin (HbAlc). - the optimal goal to achieve is HbAlc less than or equal to 6.5%. - when the HbA1c is between 6.6 and 8% on two successive controls, a modification of the treatment can be envisaged according to the clinician's assessment of the advantages / disadvantages of the proposed change of treatment - when the HbAlc is greater than 8% on two successive controls, a modification of the treatment is recommended (professional agreement). The third step is dual oral therapy. In the event of primary or secondary failure of the initial oral monotherapy, it is recommended to prescribe dual oral therapy, ie to associate two classes of hypoglycemic agents with one another. The fourth step is insulin therapy. If a type II diabetic remains poorly balanced, switch to insulin treatment. Insulin therapy provides a clear improvement in glycemic control. If this is not the case, we can associate insulin therapy prescription biguanides that potentiate the action. The object of the invention is therefore to propose a novel pharmaceutical and / or dietary composition which acts as an antidiabetic, without any significant side effects.
Exemples non exhaustifs de quelques préparations des principes actifs de la composition pharmaceutique etlou diététique selon l'invention: Exemples de la formulation de la composition nommée Dirnole® non limitatif Tableau 1 Noms Pourcentage harungana madagascriensis 5 - 30 % gnetum spp 10 - 40 % dioscorea spp 5-40 % Vernonia amygdalina 10-50% Il a été trouvé de manière inattendue que l'administration par voie orale (per os) d'une quantité efficace du mélange d'un extrait aqueux du Dimole provoquait une réduction significative de la glycémie chez l'homme lorsqu'il est administré 3 fois par jour. Plusieurs articles scientifiques décrivent aussi l'utilisation des extraits totaux de certaines des ces plantes séparément ou avec d'autres plantes sous forme de décoction ou d'infusion comme médicaments antidiabétiques traditionnelles. Il en est ainsi de Vernonia amygdalina qui est utilisé au Nigeria dans le district de Lagos comme un antidiabétique (Journal of Ethnopharmacology 121 ,2009, 135-139). Mise en oeuvre de l'invention : Le Dimole® L'invention est actuellement mise en oeuvre sous le nom de «Dimole ®» dont le principe actif est une 15 combinaison de l'extrait aqueux de harungana madagascriensis, de gnetum spp, de dioscorea spp, de vernonia amygdalina. A titre d'exemple non limitatif mais portant sur un modèle de réalisation de la formulation, le principe actif de Dirnole® peut être réalisé avec une concentration des extraits aqueux selon la formule du tableau ci-dessus.Non-exhaustive examples of some preparations of the active ingredients of the pharmaceutical and / or dietetic composition according to the invention: Examples of the formulation of the composition named Dirnole® which is not limiting Table 1 Names Percentage harungana madagascriensis 5 - 30% gnetum spp 10 - 40% dioscorea spp 5-40% Vernonia amygdalina 10-50% It has been unexpectedly found that the oral (oral) administration of an effective amount of the mixture of an aqueous extract of Dimole causes a significant reduction of blood glucose in the man when given 3 times a day. Several scientific articles also describe the use of the total extracts of some of these plants separately or with other plants in the form of a decoction or infusion as traditional antidiabetic drugs. This is the case of Vernonia amygdalina, which is used in Nigeria in Lagos district as an antidiabetic agent (Journal of Ethnopharmacology 121, 2009, 135-139). Application of the invention: Dimole® The invention is currently implemented under the name "Dimole®" whose active ingredient is a combination of the aqueous extract of harungana madagascriensis, gnetum spp, dioscorea spp, of vernonia amygdalina. As a non-limiting example but relating to an embodiment of the formulation, the active ingredient of Dirnole® can be produced with a concentration of aqueous extracts according to the formula of the table above.
20 Dans ses différentes formulations, et par exemple celles mentionnées ci-dessus, la composition peut aussi être présentée sous forme de comprimés, de gélules ou de poudre pour dilution ou sirop, ou tisane, ou thé, ou infusion, ou sous forme de granulé, voir tout autres formes utilisées par les hommes du métier. Cette poudre peut ne contenir que les principes actifs, et est obtenue par exemple par atomisation, ou séchage, ou lyophilisation à partir de l'extrait aqueux.In its various formulations, and for example those mentioned above, the composition may also be presented in the form of tablets, capsules or powder for dilution or syrup, or herbal tea, or tea, or infusion, or in granular form. see all other forms used by those skilled in the art. This powder may contain only the active ingredients, and is obtained for example by atomization, or drying, or lyophilization from the aqueous extract.
2961400 Exemple de préparation de l'extrait aqueux Les extraits des feuilles et/ou tiges des plantes qui constituent les différents principes actifs séchés ou frais, sont broyés de préférence à froid. Le broyat alors est mélangée à l'eau puis laissée à macération. La macération obtenue est ensuite filtrée et utilisée à l'état ou alors atomisée pour obtenir une poudre 5 fine. Le produit obtenu après filtration de la macération peut aussi être séché soit à l'étuve, soit au four, soit lyophilisé. Cette opération peut se faire individuellement sur chaque plante, ou alors à partir d'un mélange des différentes plantes. Les différentes poudres de tous les plantes selon les différentes formulations sont ensuite mélangées pour obtenir le principe actif de Dirnole®.Example of Preparation of the Aqueous Extract The extracts of the leaves and / or stems of the plants which constitute the various dried or fresh active ingredients are preferably ground cold. The ground material is then mixed with water and left to macerate. The maceration obtained is then filtered and used in the state or atomized to obtain a fine powder. The product obtained after filtration of the maceration may also be dried either in an oven, oven or lyophilized. This operation can be done individually on each plant, or from a mixture of different plants. The different powders of all the plants according to the different formulations are then mixed to obtain the active ingredient of Dirnole®.
10 L'homme du métier connait et utilise différents excipients comme liants ou lubrifiants pour fabriquer les poudres, les granulés ou autres préparations. Des exemples d'excipients qui peuvent être ainsi utilisés selon l'invention sont: le lactose, l'amidon, la dextrine, le phosphate de calcium, le carbonate de calcium, le silicate d'aluminium naturel ou synthétique, l'oxyde de magnésium, l'hydroxyde d'aluminium hydraté, le stéarate de magnésium, le bicarbonate de sodium. D'autres excipients non cités ci-dessus mais qui conviennent également sont décrits dans le « Remington's Pharmaceutical Sciences » par E.W. Martin, et peuvent être utilisés selon l'invention. Les comprimés ou autres formes galéniques sont alors réalisés selon des méthodes connues par l'homme du métier. Those skilled in the art know and use different excipients as binders or lubricants for making powders, granules or other preparations. Examples of excipients which can be so used according to the invention are: lactose, starch, dextrin, calcium phosphate, calcium carbonate, natural or synthetic aluminum silicate, magnesium oxide , hydrated aluminum hydroxide, magnesium stearate, sodium bicarbonate. Other excipients not mentioned above but which are also suitable are described in "Remington's Pharmaceutical Sciences" by E.W. Martin, and may be used according to the invention. Tablets or other galenic forms are then made according to methods known to those skilled in the art.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1002574A FR2961400B1 (en) | 2010-06-18 | 2010-06-18 | PHARMACEUTICAL OR DIETETIC COMPOSITION AS ANTIDIABETIC |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1002574A FR2961400B1 (en) | 2010-06-18 | 2010-06-18 | PHARMACEUTICAL OR DIETETIC COMPOSITION AS ANTIDIABETIC |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2961400A1 true FR2961400A1 (en) | 2011-12-23 |
| FR2961400B1 FR2961400B1 (en) | 2013-08-16 |
Family
ID=43304039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1002574A Expired - Fee Related FR2961400B1 (en) | 2010-06-18 | 2010-06-18 | PHARMACEUTICAL OR DIETETIC COMPOSITION AS ANTIDIABETIC |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2961400B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2997016A1 (en) * | 2012-10-18 | 2014-04-25 | Clarins Lab | Use of an extract of Harungana madagascariensis in a moisturizing cosmetic composition that is useful for treating dry and/or dehydrated skins |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019580A (en) * | 1989-12-19 | 1991-05-28 | Shaman Pharmaceuticals, Inc. | Dioscoretine and its use as a hypoglycemic agent |
| WO1998025639A1 (en) * | 1996-12-10 | 1998-06-18 | Shaman Pharmaceuticals, Inc. | HYPOGLYCEMIC AGENTS FROM HARUNGANA OR $i(VISMIA SPP.) |
| US6531461B1 (en) * | 2001-06-04 | 2003-03-11 | Louis Obyo Obyo Nelson | Medicament for the treatment of diabetes |
| WO2007146427A2 (en) * | 2006-06-14 | 2007-12-21 | National Yang-Ming University | Method for treating diabetic vascular complications |
| JP2009013123A (en) * | 2007-07-06 | 2009-01-22 | Hosoda Shc:Kk | Health-retaining preparation |
| JP2009249320A (en) * | 2008-04-04 | 2009-10-29 | Hosoda Shc:Kk | Obesity- and diabetes-ameliorating agent |
-
2010
- 2010-06-18 FR FR1002574A patent/FR2961400B1/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5019580A (en) * | 1989-12-19 | 1991-05-28 | Shaman Pharmaceuticals, Inc. | Dioscoretine and its use as a hypoglycemic agent |
| WO1998025639A1 (en) * | 1996-12-10 | 1998-06-18 | Shaman Pharmaceuticals, Inc. | HYPOGLYCEMIC AGENTS FROM HARUNGANA OR $i(VISMIA SPP.) |
| US6531461B1 (en) * | 2001-06-04 | 2003-03-11 | Louis Obyo Obyo Nelson | Medicament for the treatment of diabetes |
| WO2007146427A2 (en) * | 2006-06-14 | 2007-12-21 | National Yang-Ming University | Method for treating diabetic vascular complications |
| JP2009013123A (en) * | 2007-07-06 | 2009-01-22 | Hosoda Shc:Kk | Health-retaining preparation |
| JP2009249320A (en) * | 2008-04-04 | 2009-10-29 | Hosoda Shc:Kk | Obesity- and diabetes-ameliorating agent |
Non-Patent Citations (3)
| Title |
|---|
| "AGENT AND A FUNCTIONAL FOOD FOR TREATMENT OF DIABETES - COMPRISES RHIZOME AND BULBIL OF DIOSCOREA BULBIFERA", WPI DERWENT, 27 June 1996 (1996-06-27), XP002990410 * |
| DATABASE WPI Week 200910, Derwent World Patents Index; AN 2009-E13853, XP002618359 * |
| GBOLADE ET AL: "Inventory of antidiabetic plants in selected districts of Lagos State, Nigeria", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE, vol. 121, no. 1, 12 January 2009 (2009-01-12), pages 135 - 139, XP025842630, ISSN: 0378-8741, [retrieved on 20081101], DOI: DOI:10.1016/J.JEP.2008.10.013 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2997016A1 (en) * | 2012-10-18 | 2014-04-25 | Clarins Lab | Use of an extract of Harungana madagascariensis in a moisturizing cosmetic composition that is useful for treating dry and/or dehydrated skins |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2961400B1 (en) | 2013-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3533454B1 (en) | Composition comprising a mixture of plant extracts or a mixture of molecules contained in said plants and use to act on the carbohydrate and/or lipid metabolism | |
| EP1868454B1 (en) | Composition for nutritionally improving glucose control and insulin action | |
| El-Refaei et al. | Alternative medicine in diabetes-role of angiogenesis, oxidative stress, and chronic inflammation | |
| JP4199448B2 (en) | Pharmaceutical agent comprising sugarcane polyphenol-containing substance as active ingredient and use thereof | |
| EP2770853B1 (en) | Dietetic product for use in the prevention of the risk of a cardiovascular metabolic disorder | |
| US6147108A (en) | Method for treating type II diabetes mellitus | |
| US20200188468A1 (en) | A coated costus composition enriched with triterpenoids and a method of preparation of the same | |
| EP2274000B1 (en) | Pharmaceutical or dietetic composition comprising an aqueous extracts of nigella sativa and olea europea and/or phyllantus amarus | |
| KR100831621B1 (en) | The plant extracts composition for the blood glucose reducing action | |
| Al-Hayaly et al. | Effect of olive leaves extract on alloxan induced diabetes in male albino mice | |
| FR2961400A1 (en) | Composition, useful as antidiabetic drug, comprises mixture of aqueous extracts comprising Harungana madagascriensis, Gnetum species, Dioscorea species and Vernonia amygdalina | |
| Winifred et al. | Biochemical studies of the ameliorating effects of bitter leaf and scent leaf extracts on diabetes mellitus in humans | |
| WO1999053936A1 (en) | Hypoglycemic agents | |
| US20110195139A1 (en) | Use of overground part of hedychium coronarium koenig in reducing blood glucose; extracts and compositions of overground part of hedychium coronarium koenig and their uses | |
| CA2596200A1 (en) | Herbal product comprising cinnamon and coffee | |
| EP3209284B1 (en) | Anthostema senegalense-based composition, for use as an anti-aids drug | |
| CN108720013A (en) | The formula and processing technology of the health food of one group of Soboring-up liver-protecting being made of fructose and tea extract | |
| US11273191B2 (en) | Administering compositions for improved immune system functioning | |
| US6908632B1 (en) | Blood glucose modulating compositions and methods | |
| FR2931664A1 (en) | PLANT COMPOSITIONS AND USES | |
| RU2020952C1 (en) | Species of medicinal plants "glaja", "darja", "elena", "eva" showing general restorative and antisclerotic effect | |
| HUE031086T2 (en) | Use of overground part of hedychium coronarium koenig in reducing blood glucose; extracts and compositions of overground part of hedychium coronarium koenig and their uses | |
| EP3235510A1 (en) | Nutritional compositions for the management of glucose metabolism | |
| KR102281794B1 (en) | Composition for protecting hepatic damage on heavy metal comprising extracts from Dendropanax morbifera | |
| OA21114A (en) | Composition based on medicinal plants for the treatment of diabetes and process for obtaining it. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |
Effective date: 20130228 |
|
| RN | Application for restoration |
Effective date: 20130304 |
|
| FC | Decision of inpi director general to approve request for restoration |
Effective date: 20130702 |
|
| PLFP | Fee payment |
Year of fee payment: 6 |
|
| CD | Change of name or company name |
Owner name: ASSOCIATION DE NOUVELLES SCIENCES ET DES TECHN, FR Effective date: 20151019 |
|
| PLFP | Fee payment |
Year of fee payment: 7 |
|
| PLFP | Fee payment |
Year of fee payment: 8 |
|
| PLFP | Fee payment |
Year of fee payment: 9 |
|
| PLFP | Fee payment |
Year of fee payment: 11 |
|
| PLFP | Fee payment |
Year of fee payment: 12 |
|
| PLFP | Fee payment |
Year of fee payment: 13 |
|
| ST | Notification of lapse |
Effective date: 20240205 |